0
Aravive, Inc. Banner Image

Aravive, Inc.

  • Ticker ARAV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aravive, Inc. Logo Image
  • 11-50 Employees
  • Based in Houston, Texas
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinumMore resistant ovarian cancer and selected 15 mg/kg as the dose for the next potential pivotal trial. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year.
REPORT RATINGS
4.8 / 5.0 (112)

Aravive, Inc. reports have an aggregate usefulness score of 4.8 based on 112 reviews.

Aravive, Inc.

Most Recent Annual Report

Aravive, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Aravive, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!